ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintTitle ChevronIcon Twitter
Caixin

Viral shedding in coronavirus patients takes longer than thought

Researchers say median duration for expulsion in survivors required 20 days

The critical isolation unit of the Red Cross Hospital in Wuhan, China, on Jan. 24. Photo: Ding Gang/Caixin
The critical isolation unit of the Red Cross Hospital in Wuhan, Hubei province, Jan. 24. Photo: Ding Gang/Caixin

A newly published paper identifies the risk factors and clinical course of patients who died from Covid-19 and suggests for the first time that surviving patients take far longer to shed the virus than expected.

The paper, produced by a team led by China-Japan Friendship Hospital Vice President Cao Bin and published on March 9 by the prestigious medical journal The Lancet, is the first research focusing on fatal cases of coronavirus disease. It may provide important clinical guidelines to help doctors anticipate mild patients turning into severe cases, Cao said.

Cao was part of the first expert panel dispatched by the National Health Commission to the city of Wuhan on Dec. 31 to investigate the outbreak. He is also in charge of clinical trials using Gilead Sciences' remdesivir to treat Covid-19 patients in China.

The study of 191 patients, of whom 54 died before Jan. 31, found increasing probability of death associated with older age, higher organ failure and higher d-dimer, an indicator that may signal a significant blood clot.

The paper also found that the median duration of viral shedding was 20 days in survivors, but the virus was detectable until death in non-survivors. The longest observed duration of viral shedding in survivors was 37 days, and the shortest was eight days.

Viral shedding refers to the expulsion and release of virus progeny following successful reproduction during a host-cell infection. Once replication has been completed and the host cell is exhausted of all resources in making viral progeny, the viruses may begin to leave the host.

The level and duration of virus replication are important factors in assessing transmission risk and to guide decision-making in treatment and quarantine, the paper says. In an interview with The Lancet, Cao said the median duration of 20 days completely overturns previous assumptions on the detoxification time for acute respiratory virus infection. Longer viral shedding also means longer treatment and quarantine times, he said.

Antiviral drugs seem to have little effect in shortening the viral shedding period, the study suggested. Among the 29 patients who received lopinavir/ritonavir, a medication for the treatment and prevention of HIV/AIDS, the median duration of viral shedding was 22 days.

Cao noted that these patients started the medication late. The median time from their illness to initiation of antiviral treatment was 14 days. This means Covid-19 patients may need stronger, earlier antiviral treatment. A combination of two or more kinds of antiviral drugs might be needed, but any effective treatment still needs further research, Cao said.

The study confirmed that older age is associated with death in Covid-19 patients. Among the 191 patients, the median age for fatal cases was 69, while the median age for survivors was 56.

The research also associates a higher sequential organ failure assessment (SOFA) score to death cases. The score is a good diagnostic marker for sepsis and septic shock and reflects the degree of multi-organ dysfunction.

Sepsis was the most frequently observed complication for Covid-19 patients. Usually sepsis is caused by bacterial infections, but viral infection can also cause sepsis syndrome. Cao's study found that more than half of Covid-19 patients developed sepsis even without bacterial infections, but further research is needed to investigate the cause of sepsis in Covid-19 cases.

Researchers also found that cardiac complications are common in patients. Increased high-sensitivity cardiac troponin I, an indicator of heart injury, was found in more than half of those who died, and this indicator increased rapidly from day 16 of illness in nonsurvivors, but decreased from day 13 for survivors. The autopsy of a 53-year-old female patient in Jinyintan Hospital showed acute heart attack, according to the paper.

Cao's team studied the whole clinical course of the 191 patients from illness onset to discharge or death and found the median illness duration for survivors was 22 days, while the median time to death was 18.5 days.

Among the 54 fatalities, 32 patients required invasive mechanical ventilation. Extracorporeal membrane oxygenation, commonly known as ECMO, an expensive and potentially lifesaving treatment used for patients with severe organ failure, was used for three patients, none of whom survived.

Cao and his team acknowledged that the findings have some limitations. For example, not all laboratory tests were done for all patients, so the role of certain indicators might be underestimated in predicting death. The patients in the study were from two Wuhan hospitals designated for severe patients, so the death rate in the study can't reflect the overall mortality rate of Covid-19.

--

Read also the original story.

Caixinglobal.com is the English-language online news portal of Chinese financial and business news media group Caixin. Nikkei recently agreed with the company to exchange articles in English.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more